Xenon decreases cell migration and secretion of a pro-angiogenesis factor in breast adenocarcinoma cells: Comparison with sevoflurane

British Journal of Anaesthesia

Volumn 113, Issue SUPPL. 1, 2014, Pages

  Ash, S A ^a,b   Valchev, G I ^a,b   Looney, M ^a,b   Ni Mhathuna, A ^a   Crowley, P D ^a   Gallagher, H C ^a   Buggy, D J ^a,b,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

anaesthetics sevoflurane; anaesthetics xenon; cancer angiogenesis; cancer breast; cell function migration

Indexed keywords

ANGIOGENIC FACTOR; GLIPIZIDE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; RANTES; SEVOFLURANE; XENON;

ARTICLE; BIOCHEMICAL EQUIPMENT; BREAST ADENOCARCINOMA; CARCINOMA CELL; CELL MIGRATION; CELL MIGRATION ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; METASTASIS POTENTIAL; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE;

ANAESTHETICS, SEVOFLURANE; ANAESTHETICS, XENON; CANCER, ANGIOGENESIS; CANCER, BREAST; CELL FUNCTION, MIGRATION;

ADENOCARCINOMA; ANESTHETICS, INHALATION; ANGIOGENESIS INDUCING AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; CELL SURVIVAL; FEMALE; HUMANS; MCF-7 CELLS; METHYL ETHERS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; XENON;

EID: 84904966132     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu191     Document Type: Article

References (41)

1. Cancer Research UK. Breast Cancer Key Facts. Available from http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/breast-cancer/ (accessed 28 February 2014)
2. Hanahan D, Weinberg RA. Hall marks of cancer: the next generation. Cell 2011; 144: 646-74
3. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factorson cancer recurrence. Br J Anaesth 2010; 105: 106-15
4. Ash SA, Buggy DJ. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? Anupdateofavailable evidence. Best Pract Res Clin Anaes-thesiol 2013; 27: 441-56
5. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 2012; 109 (Suppl. 1): i17-28
6. Neeman E, Ben-Eliyahu S. Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun 2013; 30 (Suppl.): S32-40
7. Molloy TJ, Bosma AJ, Baumbusch LO, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 2011; 13: R61
8. Bidard FC, Vincent-Salomon A, Gomme S, et al. Disseminated tumor cellsofbreast cancer patients: astrong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14: 3306-11
9. Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp Clin Trials 2008; 29: 517-26
10. Huitink JM, Heimerikxs M, Nieuwland M, et al. Volatile anesthetics modulate gene expression in breast and brain tumor cells. Anesth Analg 2010; 111: 1411-5
11. Loop T, Dovi-Akue D, Frick M, et al. Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology 2005; 102: 1147-57
12. Benzonana LL, Perry NJ, Watts HR, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology 2013; 119: 593-605
13. Ecimovic P, McHugh B, Murray D, Doran P, Buggy DJ. Effects of sevo-flurane on breast cancer cell function in vitro. Anticancer Res 2013; 33: 4255-60
14. Goto T, Saito H, Nakata Y, Uezono S, Ichinose F, Morita S. Emergence times from xenon anaesthesia are independent of the duration of anaesthesia. Br J Anaesth 1997; 79: 595-9
15. Ma D, Wilhelm S, Maze M, Franks NP. Neuroprotective and neuro-toxic properties of the 'inert' gas, xenon. Br J Anaesth 2002; 89: 739-46
16. Stockert JC, Blazquez-Castro A, Canete M, Horobin RW, Villanueva A. MTTassayforcellviability: Intracellular localizationofthe formazan product is in lipid droplets. Acta Histochem 2012; 114: 785-96
17. Gough W, Hulkower KI, Lynch R, et al. A quantitative, facile, and high-throughput image-based cell migrationmethodisarobust alternative to the scratch assay. J Biomol Screen 2011; 16: 155-63
18. Dingley J, King R, Hughes L, et al. Exploration of xenonasa potential cardiostable sedative: a comparison with propofol after cardiac surgery. Anaesthesia 2001; 56: 829-35
19. Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37: 501-6
20. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58: 182-93
21. Ma D, Sanders RD, Halder S, Rajakumaraswamy N, Franks NP, Maze M. Xenon exerts age-independent antinociception in Fischer rats. Anesthesiology 2004; 100: 1313-8
22. Baur CP, Klingler W, Jurkat-Rott K, et al. Xenon does not induce con-tracture in human malignant hyperthermia muscle. Br J Anaesth 2000; 85: 712-6
23. Wei H, Liang G, Yang H, et al. The common inhalational anesthetic isoflurane induces apoptosis via activation of inositol 1, 4, 5-trisphosphate receptors. Anesthesiology 2008; 108: 251-60
24. Mitsuhata H, Shimizu R, Yokoyama MM. Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol 1995; 17: 529-34
25. Muller-Edenborn B, Roth-Z'graggen B, Bartnicka K, et al. Volatile anesthetics reduce invasion of colorectal cancer cells through down-regulation of matrix metalloproteinase-9. Anesthesiology 2012; 117: 293-301
26. Fleischmann E, Marschalek C, Schlemitz K, et al. Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. BMC Anesthesiol 2009; 9: 1
27. North WG, Gao G, Memoli VA, Pang RH, Lynch L. Breast cancer expresses functional NMDA receptors. Breast Cancer Res Treat 2010; 122: 307-14
28. Luksch H, Uckermann O, Stepulak A, et al. Silencing of selected glu-tamate receptor subunits modulates cancer growth. Anticancer Res 2011; 31: 3181-92
29. Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks SP, Dickinson R. Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-D-aspartate receptor glycine site. Anesthesiology 2013; 119: 1137-48
30. Cross BM, Breitwieser GE, Reinhardt TA, Rao R. Cellular calcium dynamics in lactation and breast cancer: from physiology to pathology. Am J Physiol Cell Physiol 2013; 306: C515-26
31. Leanza L, Biasutto L, Manago A, Gulbins E, Zoratti M, Szabo I. Intra-cellular ion channels and cancer. Front Physiol 2013; 4: 227
32. Bantel C, Maze M, Trapp S. Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener. Anesthesiology 2010; 112: 623-30
33. Lange M, Szabo C, Van Aken H, et al. Short-term effects of glipizide (an adenosine triphosphate-sensitive potassium channelinhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 2006; 26: 516-21
34. Ru Q, Tian X, Wu YX, Wu RH, Pi MS, Li CY. Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma. Oncol Rep 2013; 31: 842-8
35. Gonzalez RM, Daly DS, Tan R, Marks JR, Zangar RC. Plasma bio marker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 2011; 20: 1543-51
36. Velasco-Velazquez M, Pestell RG. The CCL5/CCR5 axispromotesme-tastasis in basal breast cancer. Oncoimmunology 2013; 2: e23660
37. Lv D, Zhang Y, Kim HJ, Zhang L, Ma X. CCL5 as a potential immu-notherapeutic target in triple-negative breast cancer. Cell Mol Immunol 2013; 10: 303-10
38. Zhang Y, Lv D, Kim HJ, et al. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013; 23: 394-408
39. Deegan CA, Murray D, Doran P, et al. Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med 2010; 35: 490-5
40. Looney M, Doran P, Buggy DJ. Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor beta in women undergoing anesthesia and surgery for breast cancer. Anesthesiology 2010; 113: 1118-25
41. Ma D, Lim T, Xu J, et al. Xenonp reconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009; 20: 713-20